High Growth Revenue STAAR reported strong Q2 2026 preliminary net sales expected to exceed 90 million, up from 44.3 million in the prior year period, signaling a rapidly expanding market for implantable Collamer Lenses that sales teams can leverage in outreach to ophthalmology practices and distribution partners.

Global Market Reach With EVO ICL products marketed in over 75 countries and manufacturing/packaging facilities in the US and Switzerland, there are ample cross-border sales opportunities, channel partnerships, and regional support needs to address in new or existing territories.

Strategic Alliances Recent integration with AMICO Group and a shift in executive leadership present openings to align joint go-to-market strategies, distribution expansion, and localized service offerings that can accelerate sales cycles with clinics and hospital networks.

Sustainable Differentiator STAAR’s proprietary biocompatible Collamer material and foldable ICLs enable smaller incisions and faster recovery, presenting a value proposition for clinics focused on patient outcomes, reduced complication risk, and faster throughput—key talking points for upsell to surgeons.

Operational Scale Given the company’s size (501-1000 employees) and revenue between 250M-500M, there is potential for expanding after-sales services, training, and consumables supply agreements (packaging, distribution, and service contracts) to deepen recurring revenue with established ophthalmology centers.